
## Glaucia Chiyoko Akutagava-Martins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9118317/publications.pdf Version: 2024-02-01



**GLAUCIA CHIYOKO** 

#	Article	IF	CITATIONS
1	Assessing undertreatment and overtreatment/misuse of ADHD medications in children and adolescents across continents: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2021, 128, 64-73.	6.1	13
2	Are ADHD medications under or over prescribed worldwide?. Medicine (United States), 2018, 97, e10923.	1.0	9
3	COMT and DAT1 genes are associated with hyperactivity and inattention traits in the 1993 Pelotas Birth Cohort: evidence of sex-specific combined effect. Journal of Psychiatry and Neuroscience, 2016, 41, 405-412.	2.4	17
4	NOS1 and SNAP25 polymorphisms are associated with Attention-Deficit/Hyperactivity Disorder symptoms in adults but not in children. Journal of Psychiatric Research, 2016, 75, 75-81.	3.1	14
5	Genetics of attention-deficit/hyperactivity disorder: an update. Expert Review of Neurotherapeutics, 2016, 16, 145-156.	2.8	71
6	MAP1B and NOS1 genes are associated with working memory in youths with attention-deficit/hyperactivity disorder. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 359-366.	3.2	9
7	<i>LPHN</i> 3 and attentionâ€deficit/hyperactivity disorder: a susceptibility and pharmacogenetic study. Genes, Brain and Behavior, 2015, 14, 419-427.	2.2	58
8	Lack of association between the GRM7 gene and attention deficit hyperactivity disorder. Psychiatric Genetics, 2014, 24, 281-282.	1.1	7
9	Glutamatergic copy number variants and their role in attentionâ€deficit/hyperactivity disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 502-509.	1.7	32
10	ADHD pharmacogenetics across the life cycle: New findings and perspectives. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 263-282.	1.7	40
11	Genetics of attention-deficit/hyperactivity disorder: current findings and future directions. Expert Review of Neurotherapeutics, 2013, 13, 435-445.	2.8	55